Sheila Tan
YOU?
Author Swipe
View article: Oral misoprostol ( <scp>PGE1</scp> ) <i>vs</i> vaginal dinoprostone ( <scp>PGE2</scp> ) for labor induction: individual participant data meta‐analysis of randomized controlled trials
Oral misoprostol ( <span>PGE1</span> ) <i>vs</i> vaginal dinoprostone ( <span>PGE2</span> ) for labor induction: individual participant data meta‐analysis of randomized controlled trials Open
Objective To compare the effectiveness and safety of oral misoprostol vs vaginal dinoprostone for the induction of labor (IOL) using an individual participant data (IPD) meta‐analysis. Methods We used a Cochrane review and searched Ovid ME…
View article: Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML Open
Background: The menin inhibitor revumenib (previously SNDX-5613), is a potent, oral, selective inhibitor of the menin-KMT2A interaction which is a dependency in acute leukemia caused by either rearrangement of the KMT2A (KMT2Ar) or Nucleop…
View article: P590: PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)
P590: PRELIMINARY SAFETY AND EFFICACY OF BGB-11417, A POTENT AND SELECTIVE B-CELL LYMPHOMA 2 (BCL2) INHIBITOR, IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) Open
Background: BCL2, a key regulator of apoptosis promoting cancer cell survival, is aberrantly expressed in many hematologic malignancies. The BCL2 inhibitor, venetoclax, is standard of care for the treatment of newly diagnosed AML in adults…